5 results about "Adenosine a" patented technology

Adenosine A 2A Receptor (A 2A R) or adenosine A 2B Receptor (A 2B The present invention provides a pharmaceutical composition for the treatment of a disease, disorder, or condition at least partially mediated by R). [Solution] Use a compound having formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. JPEG2026086620000481.jpg45167

This invention discloses a radioactive triazolidinedimethylpyrimidine derivative, its preparation method, and its applications. The derivative has the structure shown in Formula I. Compared with the prior art, this invention provides a class of high-affinity adenosine A derivatives. 2A Radioactive triazolidinedimethyl derivatives of the receptor. This class of compounds belongs to the diagnostic category A. 2A Novel compounds for receptor-related diseases, and derivatives thereof prepared to target A 2A Imaging of the receptor, compared with previously reported targeting of A 2A Compared to receptor-specific radiopharmaceuticals, the radioactive compounds of this invention can rapidly reach equilibrium in the brain, thereby facilitating A. 2A Rapid quantification and qualitative analysis of receptors. The compounds of this invention can be applied not only to A... 2A The diagnosis of receptor-related brain diseases can also be applied to A 2A Diagnosis and efficacy evaluation of tumors with high receptor expression.

A novel humectant eye drop composition is disclosed. The composition comprises a synergistic combination of nicotinamide and adenosine in concentrations at which neither component is effective individually. In preferred embodiments of the invention, the composition comprises 0.025% (w / v) and 0.05% (w / v) nicotinamide. Within 2 - 3 weeks of commencement of application, the composition improves the Tear Film Breakup Time, improves tear production as measured by the Schirmer Test, reduces the severity of the Dry Eye Syndrome as measured by Lissamine Green staining, and shows anti-inflammatory effects.

This invention relates to a compound containing an azobenzene structure or a pharmaceutically acceptable salt, cis-trans isomer, tautomer, solvate, polymorph, or prodrug thereof; the compound provided by this invention is based on the original adenosine A... 2A Based on the structure of receptor antagonists, an azobenzene structure is introduced, making adenosine A... 2A Receptor antagonists possess light-controlled switching properties, and the compounds of this invention can act as adenosine A. 2A Receptor antagonists applied to adenosine A 2A In receptor-mediated diseases, the light-controlled switching properties of the compounds provided by this invention enable them to achieve local efficacy through light irradiation after systemic administration. Some compounds provided by this invention exhibit a fourfold increase in antagonistic activity under specific wavelengths of light irradiation, while others exhibit a fourfold decrease in antagonistic activity under specific wavelengths of light irradiation. In in vivo animal experiments, compound 1 provided by this invention significantly increases the motor ability of mice after light irradiation.

This invention relates to a class of adenosine A with ferroptosis-inhibiting activity. 2A Receptor antagonists, or pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs, or prodrugs thereof. The compounds provided by this invention are pharmacophore-fused hybrid molecules containing adenosine A. 2A The compounds possess receptor antagonist and / or ferroptosis inhibitor functions, and can be used as neuroprotective agents to prevent or treat neurodegenerative diseases. The compounds provided in this invention exhibit up to 90 times higher ferroptosis inhibitory activity and up to 2.9 times higher antioxidant activity than Trolox, and several compounds retain adenosine A equivalent to that of ZM241385. 2A Receptor antagonistic activity; in in vivo animal experiments, the compounds provided by this invention exhibit significant neuroprotective and intraocular pressure-lowering effects.